Penn Division of General Internal Medicine

@penndgim.bsky.social

Division of General Internal Medicine | The University of Pennsylvania Perelman School of Medicine | @pennmedicine.bsky.social

Check out this research letter in @jamahealthforum.com from DGIM's Matthew Klebanoff, Jalpa Doshi, and Pengxiang Li et al. on how the Inflation Reduction Act is reshaping Medicare Part D formulary coverage of MS disease-modifying therapies.

PennLDI@pennldi.bsky.social · 2mo ago

How did #Medicare Part D coverage of multiple sclerosis therapies change after the #InflationReductionAct? LDI Fellows found that after 2025, Part D plans increasingly covered generic disease-modifying therapies when available, while brand-name coverage declined. Read more: https://bit.ly/4fI7hlw

Policy Engagement Update 📣 LDI Director of Innovation Paula Chatterjee testified before the Center for Rural Pennsylvania Board of Directors on Rural Health Transformation Program funding allocations and implementation. Read the full testimony: https://bit.ly/49maEe8

Testimony: Rural Health Transformation in Pennsylvania

LDI’s Paula Chatterjee testified before the Center for Rural Pennsylvania Board of Directors on Rural Health Transformation Program funding.

ldi.upenn.edu

🏛 Last week, Penn LDI brought together researchers, Congressional staff, and policy leaders for a nonpartisan briefing in Washington, D.C. to examine the evidence on the drivers of high U.S. #healthcare costs and policy approaches to improve #affordability. Stay tuned for key takeaways, coming soon.

Penn LDI's event, "Health Care Affordability: Evidence and Federal Policy Options" on March 26, 2026, presented in partnership with Penn Washington.Aaron Schwartz, MD, PhD, Michael Anne Kyle, PhD, RN, David Grande, MD, MPA, and Rachel M. Werner, MD, PhD [left to right] at Penn LDI's event, "Health Care Affordability: Evidence and Federal Policy Options" on March 26, 2026, in Washington, D.C.